Business Description
Immunovant Inc
NAICS : 325199
SIC : 2834
ISIN : US45258J1025
Description
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2257.96 | |||||
| Equity-to-Asset | 0.96 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -3.6 | |||||
| 3-Year EPS without NRI Growth Rate | -1.9 | |||||
| 3-Year FCF Growth Rate | -7.4 | |||||
| 3-Year Book Growth Rate | 17.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 3.69 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 20.24 | |||||
| 9-Day RSI | 27.11 | |||||
| 14-Day RSI | 30.98 | |||||
| 6-1 Month Momentum % | -8.23 | |||||
| 12-1 Month Momentum % | 95.34 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 22.14 | |||||
| Quick Ratio | 22.14 | |||||
| Cash Ratio | 21.52 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -33.6 | |||||
| Shareholder Yield % | 0.03 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -60.61 | |||||
| ROA % | -54.91 | |||||
| ROIC % | -3331.49 | |||||
| ROC (Joel Greenblatt) % | -20799.62 | |||||
| ROCE % | -63.13 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 5.81 | |||||
| Price-to-Tangible-Book | 5.81 | |||||
| EV-to-EBIT | -13.18 | |||||
| EV-to-Forward-EBIT | -14.2 | |||||
| EV-to-EBITDA | -13.19 | |||||
| EV-to-Forward-EBITDA | -14.21 | |||||
| EV-to-FCF | -15.87 | |||||
| Price-to-Net-Current-Asset-Value | 5.81 | |||||
| Price-to-Net-Cash | 5.98 | |||||
| Earnings Yield (Greenblatt) % | -7.59 | |||||
| FCF Yield % | -5.33 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:IMVT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Immunovant Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.84 | ||
| Beta | 0.5 | ||
| Volatility % | 82.37 | ||
| 14-Day RSI | 30.98 | ||
| 14-Day ATR ($) | 1.375367 | ||
| 20-Day SMA ($) | 29.772 | ||
| 12-1 Month Momentum % | 95.34 | ||
| 52-Week Range ($) | 16 - 45.58 | ||
| Shares Outstanding (Mil) | 145.29 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Immunovant Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Immunovant Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Immunovant Inc Frequently Asked Questions
What is Immunovant Inc(IMVT)'s stock price today?
The current price of IMVT is $27.17. The 52 week high of IMVT is $45.58 and 52 week low is $16.00.
When is next earnings date of Immunovant Inc(IMVT)?
The next earnings date of Immunovant Inc(IMVT) is 2024-05-22 Est..
Does Immunovant Inc(IMVT) pay dividends? If so, how much?
Immunovant Inc(IMVT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers